vs

Side-by-side financial comparison of CLOVER HEALTH INVESTMENTS, CORP. (CLOV) and Symbotic Inc. (SYM). Click either name above to swap in a different company.

Symbotic Inc. is the larger business by last-quarter revenue ($630.0M vs $487.7M, roughly 1.3× CLOVER HEALTH INVESTMENTS, CORP.). Symbotic Inc. runs the higher net margin — 0.4% vs -10.1%, a 10.5% gap on every dollar of revenue. On growth, CLOVER HEALTH INVESTMENTS, CORP. posted the faster year-over-year revenue change (44.7% vs 29.4%). Over the past eight quarters, Symbotic Inc.'s revenue compounded faster (21.9% CAGR vs 18.6%).

Clover Health Investments, Corp. is an American health care company founded in 2014. The company provides Medicare Advantage (MA) insurance plans and operates as a direct contracting entity with the U.S. government. The company manages care for Medicare beneficiaries in 11 states and started trading publicly on January 8, 2021.

Symbotic Inc. is an American robotics warehouse automation company based in Wilmington, Massachusetts.

CLOV vs SYM — Head-to-Head

Bigger by revenue
SYM
SYM
1.3× larger
SYM
$630.0M
$487.7M
CLOV
Growing faster (revenue YoY)
CLOV
CLOV
+15.3% gap
CLOV
44.7%
29.4%
SYM
Higher net margin
SYM
SYM
10.5% more per $
SYM
0.4%
-10.1%
CLOV
Faster 2-yr revenue CAGR
SYM
SYM
Annualised
SYM
21.9%
18.6%
CLOV

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
CLOV
CLOV
SYM
SYM
Revenue
$487.7M
$630.0M
Net Profit
$-49.3M
$2.6M
Gross Margin
21.2%
Operating Margin
-10.1%
1.0%
Net Margin
-10.1%
0.4%
Revenue YoY
44.7%
29.4%
Net Profit YoY
-123.2%
174.9%
EPS (diluted)
$0.02

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CLOV
CLOV
SYM
SYM
Q4 25
$487.7M
$630.0M
Q3 25
$496.6M
$618.5M
Q2 25
$477.6M
$592.1M
Q1 25
$462.3M
$549.7M
Q4 24
$337.0M
$486.7M
Q3 24
$331.0M
$503.6M
Q2 24
$356.3M
$491.9M
Q1 24
$346.9M
$424.3M
Net Profit
CLOV
CLOV
SYM
SYM
Q4 25
$-49.3M
$2.6M
Q3 25
$-24.4M
$-3.6M
Q2 25
$-10.6M
$-5.9M
Q1 25
$-1.3M
$-3.9M
Q4 24
$-22.1M
$-3.5M
Q3 24
$-9.2M
$-2.5M
Q2 24
$7.4M
$-2.5M
Q1 24
$-19.2M
$-6.6M
Gross Margin
CLOV
CLOV
SYM
SYM
Q4 25
21.2%
Q3 25
20.6%
Q2 25
18.2%
Q1 25
19.6%
Q4 24
16.4%
Q3 24
24.5%
12.7%
Q2 24
30.3%
13.7%
Q1 24
23.6%
10.4%
Operating Margin
CLOV
CLOV
SYM
SYM
Q4 25
-10.1%
1.0%
Q3 25
-4.9%
-3.5%
Q2 25
-2.2%
-6.2%
Q1 25
-0.3%
-5.8%
Q4 24
-6.4%
-5.1%
Q3 24
-2.7%
-4.3%
Q2 24
2.0%
-5.1%
Q1 24
-6.5%
-12.0%
Net Margin
CLOV
CLOV
SYM
SYM
Q4 25
-10.1%
0.4%
Q3 25
-4.9%
-0.6%
Q2 25
-2.2%
-1.0%
Q1 25
-0.3%
-0.7%
Q4 24
-6.6%
-0.7%
Q3 24
-2.8%
-0.5%
Q2 24
2.1%
-0.5%
Q1 24
-5.5%
-1.6%
EPS (diluted)
CLOV
CLOV
SYM
SYM
Q4 25
$0.02
Q3 25
$-0.04
Q2 25
$-0.05
Q1 25
$-0.04
Q4 24
$-0.03
Q3 24
$-0.03
Q2 24
$-0.02
Q1 24
$-0.07

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CLOV
CLOV
SYM
SYM
Cash + ST InvestmentsLiquidity on hand
$78.3M
$1.8B
Total DebtLower is stronger
Stockholders' EquityBook value
$308.7M
$663.8M
Total Assets
$541.0M
$3.0B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CLOV
CLOV
SYM
SYM
Q4 25
$78.3M
$1.8B
Q3 25
$1.2B
Q2 25
$777.6M
Q1 25
$954.9M
Q4 24
$194.5M
$903.0M
Q3 24
$288.0M
$727.3M
Q2 24
$254.8M
$870.5M
Q1 24
$208.3M
$901.4M
Stockholders' Equity
CLOV
CLOV
SYM
SYM
Q4 25
$308.7M
$663.8M
Q3 25
$340.9M
$221.3M
Q2 25
$344.2M
$210.8M
Q1 25
$336.1M
$205.4M
Q4 24
$341.1M
$196.5M
Q3 24
$342.2M
$197.2M
Q2 24
$324.9M
$418.7M
Q1 24
$292.5M
$417.1M
Total Assets
CLOV
CLOV
SYM
SYM
Q4 25
$541.0M
$3.0B
Q3 25
$559.7M
$2.4B
Q2 25
$575.0M
$1.8B
Q1 25
$583.7M
$2.0B
Q4 24
$580.7M
$1.7B
Q3 24
$653.0M
$1.6B
Q2 24
$674.2M
$1.6B
Q1 24
$671.8M
$1.6B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CLOV
CLOV
SYM
SYM
Operating Cash FlowLast quarter
$-66.9M
$191.5M
Free Cash FlowOCF − Capex
$-69.0M
FCF MarginFCF / Revenue
-14.1%
Capex IntensityCapex / Revenue
0.4%
Cash ConversionOCF / Net Profit
73.61×
TTM Free Cash FlowTrailing 4 quarters
$-69.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CLOV
CLOV
SYM
SYM
Q4 25
$-66.9M
$191.5M
Q3 25
$12.1M
$530.7M
Q2 25
$5.4M
$-138.3M
Q1 25
$-16.3M
$269.6M
Q4 24
$34.8M
$205.0M
Q3 24
$50.0M
$-99.4M
Q2 24
$44.8M
$50.4M
Q1 24
$25.9M
$21.1M
Free Cash Flow
CLOV
CLOV
SYM
SYM
Q4 25
$-69.0M
Q3 25
$11.4M
Q2 25
$4.8M
Q1 25
$-16.5M
Q4 24
$33.3M
$197.7M
Q3 24
$49.6M
$-120.1M
Q2 24
$44.4M
$33.5M
Q1 24
$25.5M
$18.6M
FCF Margin
CLOV
CLOV
SYM
SYM
Q4 25
-14.1%
Q3 25
2.3%
Q2 25
1.0%
Q1 25
-3.6%
Q4 24
9.9%
40.6%
Q3 24
15.0%
-23.9%
Q2 24
12.5%
6.8%
Q1 24
7.3%
4.4%
Capex Intensity
CLOV
CLOV
SYM
SYM
Q4 25
0.4%
Q3 25
0.1%
Q2 25
0.1%
Q1 25
0.0%
Q4 24
0.5%
1.5%
Q3 24
0.1%
4.1%
Q2 24
0.1%
3.4%
Q1 24
0.1%
0.6%
Cash Conversion
CLOV
CLOV
SYM
SYM
Q4 25
73.61×
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
6.04×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CLOV
CLOV

Segment breakdown not available.

SYM
SYM

Systems$590.3M94%
Operation Services$28.8M5%
Software Maintenance And Support$10.9M2%
Revision Of Prior Period Change In Accounting Principle Adjustment$2.9M0%
Related Party$1.1M0%

Related Comparisons